General Information of Drug (ID: DM2KVM0)

Drug Name
BI-44847 Drug Info
Indication
Disease Entry ICD 11 Status REF
Type-2 diabetes 5A11 Phase 1 [1]
Cross-matching ID
PubChem CID
10181733
CAS Number
CAS 421592-30-5
TTD Drug ID
DM2KVM0

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dapagliflozin DM28UJG Non-insulin dependent diabetes 5A11 Approved [3]
Empagliflozin DMRF9YK Type-1 diabetes 5A10 Approved [3]
Canagliflozin DMFRM1I Non-insulin dependent diabetes 5A11 Approved [4]
PF-04971729 DM79VXT Type-2 diabetes 5A11 Approved [5]
Sotagliflozin DMMLXA9 Heart failure BD10-BD13 Approved [6]
Dapagliflozin Propanediol; Saxagliptin Hydrochloride DM34TXO Type-2 diabetes 5A11 Approved [7]
ASP1941 DMGQ1TV Liver disease DB90-BD99 Phase 3 [8]
Remogliflozin etabonate DMW4YK1 Type-1/2 diabetes 5A10-5A11 Phase 2 [9]
LIK-066 DM32NWD Heart failure BD10-BD13 Phase 2 [10]
AVE-2268 DMA42BV Diabetic complication 5A2Y Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sodium/glucose cotransporter 2 (SGLT2) TTLWPVF SC5A2_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT02211937) Relative Oral Bioavailability of BI 44847 as Suspension Compared to Tablet and the Influence of Food Anf of BI 44847 as Solution Compared to Tablet in Healthy Male Volunteers. U.S. National Institutes of Health.
2 Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes
3 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
4 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
5 Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.Diabetes Obes Metab.2015 Jun;17(6):591-8.
6 LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.World J Diabetes.2015 Feb 15;6(1):136-44.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung. 2008;58(11):574-80.